This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Sonus Networks, Novavax: Small-Cap Winner

Stocks in this article: SONS NVAX KV-A EXK PSTI STP YGE

NEW YORK ( TheStreet) -- Shares of Sonus Networks (SONS) were zooming 26% to $3.78 on unusually high volumes Tuesday after it reported better-than-expected revenue growth and also forecast revenues above analyst expectations.

Revenue increased 21 percent to $83 million, from $68.7 million in the same period a year earlier, much higher than the $68.6 million analysts predicted. Sonus said its net income rose to $11.4 million from $10.3 million in the year-ago quarter. On a per share basis, earnings were flat at 4 cents as average shares outstanding increased in the 2010 period. Analysts surveyed by FactSet forecast earnings of 3 cents per share.

For 2011, Sonus said it expects revenue of $265 million to $285 million, higher than the $242.3 million analysts are currently expecting.

Novavax (NVAX), which develops recombinant vaccines for infectious diseases, saw its shares rise 11% to $2.89 after it said it had been awarded a $179 million contract by the office of Biomedical Advanced Research and Development Authority (BARDA) for the advanced clinical and manufacturing development of recombinant vaccines for the prevention of seasonal and pandemic influenza.

During the contract's 3-year base period, valued at $97 million, Novavax will develop and manufacture its clinical-stage, recombinant virus-like particle (VLP) influenza vaccines. The contract could be extended for an additional 24-month option period with $82 million in additional funding to build on the work Novavax accomplishes during the base period and to support manufacturing scale-up and licensure by the U.S. Food & Drug Administration.

Shares of KV Pharmaceuticals (KV-A) were soaring 7.6% to $8.73. The company said Tuesday that it had completed a private debt placement of $200 million, the proceeds of which will be used to repay debt obligations.

Endeavour Silver (EXK) was gaining 8.7% to $8.06. Silver miners are in the spotlight as silver continued to outshine gold.

Shares of Pluristem Therapeutics (PSTI) were up 6% to $2.62 after the company announced that a preclinical study demonstrating that the local administration of PLX cells following muscle injury resulted in a significant improvement in the recovery of muscle function when compared with the control group. WBB Securities initiated coverage on the stock with a "speculative buy".

Solar stocks Suntech Power (STP) and Yingli Energy (YGE) were up about 4% each. Solar stocks fell on Monday after analyst reports indicated that a new draft being introduced this week in Italian parliament would cap solar installations at 8 gigawatts, and the cap would be implemented immediately and with no grandfathering clause.

--Written by Shanthi Bharatwaj in New York



>To contact the writer of this article, click here: Shanthi Bharatwaj.

>To follow the writer on Twitter, go to http://twitter.com/shavenk.

>To submit a news tip, send an email to: tips@thestreet.com.

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs